Morphologic and metabolic abnormalities in vertically HIV-infected children and youth.
about
Dyslipidemia, Diet and Physical Exercise in Children on Treatment With Antiretroviral Medication in El Salvador: A Cross-sectional StudyGetting to 90-90-90 in paediatric HIV: What is needed?Aggregate risk of cardiovascular disease among adolescents perinatally infected with the human immunodeficiency virus.Total body and spinal bone mineral density across Tanner stage in perinatally HIV-infected and uninfected children and youth in PACTG 1045.LIPODYSTROPHY SYNDROME IN HIV-INFECTED CHILDREN ON HAART.Antiretroviral treatment for children with peripartum nevirapine exposure.Longitudinal assessment of metabolic abnormalities in adolescents and young adults with HIV-infection acquired perinatally or in early childhoodBody fat redistribution and metabolic abnormalities in HIV-infected patients on highly active antiretroviral therapy: novel insights into pathophysiology and emerging opportunities for treatment.Lipid and glucose alterations in perinatally-acquired HIV-infected adolescents and young adults.Immunologic and virologic failure after first-line NNRTI-based antiretroviral therapy in Thai HIV-infected children.Echocardiography and carotid intima-media thickness among asymptomatic HIV-infected adolescents in Thailand.Body fat distribution in perinatally HIV-infected and HIV-exposed but uninfected children in the era of highly active antiretroviral therapy: outcomes from the Pediatric HIV/AIDS Cohort Study.Using cluster heat maps to investigate relationships between body composition and laboratory measurements in HIV-infected and HIV-uninfected children and young adultsLipid profiles in young HIV-infected children initiating and changing antiretroviral therapy.Metabolic abnormalities and body composition of HIV-infected children on Lopinavir or Nevirapine-based antiretroviral therapy.Switching children previously exposed to nevirapine to nevirapine-based treatment after initial suppression with a protease-inhibitor-based regimen: long-term follow-up of a randomised, open-label trialNevirapine versus ritonavir-boosted lopinavir for HIV-infected children.The physical and psychological effects of HIV infection and its treatment on perinatally HIV-infected childrenHigh prevalence of lipid abnormalities among antiretroviral-naive HIV-infected Asian children with mild-to-moderate immunosuppression.Assessment of biomarkers of cardiovascular risk among HIV type 1-infected adolescents: role of soluble vascular cell adhesion molecule as an early indicator of endothelial inflammation.High prevalence of lipoatrophy in pre-pubertal South African children on antiretroviral therapy: a cross-sectional study.Associations of Genetically Determined Continental Ancestry With CD4+ Count and Plasma HIV-1 RNA Beyond Self-Reported Race and Ethnicity.Unresolved antiretroviral treatment management issues in HIV-infected childrenParticipation and retention of youth with perinatal HIV infection in mental health research studies: the IMPAACT P1055 psychiatric comorbidity studyCardiac effects in perinatally HIV-infected and HIV-exposed but uninfected children and adolescents: a view from the United States of America.Metabolic complications and treatment of perinatally HIV-infected children and adolescents.Insulin resistance and glucose and lipid concentrations in a cohort of perinatally HIV-infected Latin American childrenFactors associated with insulin resistance among children and adolescents perinatally infected with HIV-1 in the pediatric HIV/AIDS cohort study.Second-line protease inhibitor-based HAART after failing non-nucleoside reverse transcriptase inhibitor-based regimens in Asian HIV-infected children.Lipid changes in Kenyan HIV-1-infected infants initiating highly active antiretroviral therapy by 1 year of ageAdverse bone health among children and adolescents growing up with HIV.Metabolic Disorders in HIV-Infected Adolescents Receiving Protease Inhibitors.Patterns of Growth, Body Composition, and Lipid Profiles in a South African Cohort of Human Immunodeficiency Virus-Infected and Uninfected Children: A Cross-Sectional Study.Nevirapine- Versus Lopinavir/Ritonavir-Based Antiretroviral Therapy in HIV-Infected Infants and Young Children: Long-term Follow-up of the IMPAACT P1060 Randomized Trial.Association of Dyslipidemia and Glucose Abnormalities With Antiretroviral Treatment in a Cohort of HIV-Infected Latin American Children.The Association of Fat and Lean Tissue with Whole Body and Spine Bone Mineral Density is Modified by HIV Status and Sex in Children and Youth.Safety and Efficacy of Atorvastatin in Human Immunodeficiency Virus-infected Children, Adolescents and Young Adults With Hyperlipidemia.Serum lipid and glucose profiles in HIV-positive Nigerian children.Type 2 diabetes and impaired glucose tolerance in two young adults infected with HIV early in life.PHYSICAL ACTIVITY AND BODY FAT IN ADOLESCENTS LIVING WITH HIV: A COMPARATIVE STUDY.
P2860
Q28395417-DD07EE29-9681-49E3-BDE8-EED6EA770EFDQ30385352-E0903AEC-0CFA-43E1-A993-8D6E2E45A9CEQ30576375-CC9649E2-5821-4477-87FB-F4C2EFB0E458Q33532361-2BE0E08F-10B5-4A81-97DE-8BA6143E1C6BQ34058478-6F62077C-E5B9-4D82-89D6-053060BF6C28Q34494986-1A3D82C7-340C-4E3D-9EA6-BF2D274C173CQ34495072-B5C7C195-0C0C-4A92-AE7E-8ACC16596C20Q34564973-8C3BCCEC-F79F-4546-B131-9B7604D9C973Q35257230-5A322B65-263B-4447-832E-051494CEFF4AQ35549604-425A3B1B-8C4D-41BD-BACF-1369AB1A1EC4Q35582669-BEA389C7-B3B6-4A34-A436-03D62F532A40Q35656425-AC62656B-4E60-470E-AD12-6F71373060EEQ35785361-41F78C0C-CA32-446F-8AF5-813E8FB9CF2EQ35926011-81C27599-1A16-42D3-8AEB-00B6B81ADCB4Q35945312-D83BCA80-6FE6-4455-BA66-743A2D7E15CAQ35965440-E1CA71B9-2B48-4797-9606-3F783EDB8519Q36238419-BF9E4095-08A5-47A2-A38D-5B5F5E55C4BAQ36349683-169A4C8C-825D-4D0F-A996-330F2B370476Q36488227-7C95E66E-14BC-4DCA-8202-D6EFBA196317Q36634946-14C2FBA7-549F-4609-BB14-0FB2047B8428Q36646867-C0632535-DBAE-46F6-A208-779A2F45F762Q36678096-0A38658C-7652-448D-AB05-7D5C011AFEC2Q36781481-F5C3C5BA-7B2C-430B-A263-1975E35F9293Q36930477-BB6BE2E5-385E-4115-91FE-63EBBF3F388EQ36941650-E36C24EE-E254-45A6-99B0-6255B6A5A174Q36952291-2FA9DAB0-95D5-41E5-BF44-F9A4F4BF8D14Q36961612-EB9C75ED-FD8F-4AD9-812A-646653CD6D7FQ36969459-82A259F8-896B-46DC-9BF9-D94652D61EF2Q37025153-21EEF30C-FDE7-4325-8AE5-EF8D43A4AB24Q37080086-2A366BA5-BB65-4196-BE82-17A5FE8D0BB6Q37098360-99BDA771-96C8-498B-B16A-C7BD98A1AB00Q37673041-E225A72D-D8BF-4ED9-B886-D53622CEFE4CQ38798094-6235453F-EB8B-4FF5-AF0F-365152E8AE03Q38853723-95AC91E6-EBAD-4AC5-8676-9A8AEC60D3EEQ39444280-D362BACA-14A7-47BF-9714-58639FD70602Q40089986-28FFAB2F-74D9-4BE4-8626-D0D419F43C66Q40504034-215E8FDE-5D74-42F5-A3EE-166ED9B63F06Q42334793-37D139B8-777B-4172-9338-3C890B2A2352Q42613541-1A51A8F8-AB41-423C-BF57-3639C2889792Q43089961-65255CEF-675D-4227-82E5-1631B3E6DCE4
P2860
Morphologic and metabolic abnormalities in vertically HIV-infected children and youth.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on March 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Morphologic and metabolic abnormalities in vertically HIV-infected children and youth.
@en
Morphologic and metabolic abnormalities in vertically HIV-infected children and youth.
@nl
type
label
Morphologic and metabolic abnormalities in vertically HIV-infected children and youth.
@en
Morphologic and metabolic abnormalities in vertically HIV-infected children and youth.
@nl
prefLabel
Morphologic and metabolic abnormalities in vertically HIV-infected children and youth.
@en
Morphologic and metabolic abnormalities in vertically HIV-infected children and youth.
@nl
P2093
P2860
P1433
P1476
Morphologic and metabolic abnormalities in vertically HIV-infected children and youth.
@en
P2093
Amanda Zadzilka
Dana S Hardin
Denise L Jacobson
Elizabeth Sheeran
Grace M Aldrovandi
Jane C Lindsey
Kathleen Mulligan
Pediatric AIDS Clinical Trials Group P1045 team
Peggy Borum
William A Meyer
P2860
P304
P356
10.1097/QAD.0B013E3283269DFB
P407
P50
P577
2009-03-01T00:00:00Z